A Brad "Blast from the Past"Cancer history drives Oncolytics chief
Survivor developing virus-based therapy
By LEONARD ZEHR
BIOTECHNOLOGY REPORTER
Monday, August 5, 2002 – Print Edition, Page B1
Personal issues played a large role in Brad Thompson's decision to first invest in and then run chemotherapy developer Oncolytics Biotech Inc.
His mother and uncle, both long-term smokers, died of cancer in the mid-1990s and Mr. Thompson is a melanoma survivor.
"I guess I was lucky they caught it early," he recalls, noting other incidences of the disease in his family.
Now the 45-year-old microbiologist is leading a full-scale assault to develop treatments for prostate and brain cancer -- and a third cancer target to be selected this fall -- with Oncolytics' experimental drug Reolysin.
"The nice thing about this virus is that it goes into every cell, but whether it replicates or not depends on the genetics of the cancer," Mr. Thompson said. "And we haven't seen any damage to healthy cells in humans."
In April, the company began injecting Reolysin into men with prostate cancer. They will be monitored for three weeks and then the prostate will be surgically removed.
"Assuming we see positive and consistent results after about 20 patients, we'll probably stop testing and begin preparing for a late-stage trial," he said.
stockhouse post 5425153
So Dr. Brad Thompson is on record in the Aug/02 Globe and Mail stating that if they get positive and consistent prostate results after about 20 patients , they will begin preparing for a late-stage trial.
there is absolutely no mention made in that interview or elsewhere that this ph II trial was to become a proof of concept” or that it was only designed to support a ph I systemic trial (that became the next "big" thing after announcing "final" 6 patient prostate results.)
Brad at the 2004 AGM
“One thing you need to understand with clinical studies is that they are experiments. But they are experiments on humans, so once you actually derive the information you are looking for you stop, you don’t just keep experimenting for the fun of it”
stockhouse post 7951928
so no explanation whatsoever as to why there is no more late stage plan for the ph II prostate – therefore, using thompson’s own logic, we have to assume the only reason(s) why were that the results weren’t positive and/or consistent, which is contrary to what they stated when released.
Better change the story then and say all we wanted from the PH II prostate was information to support our application for a ph I systemic trial.
proboscis quoting Thompson, also from the 2004 agm, further explaining the small prostate trial size
"Why did the interim prostate results become the final results? Based on their ongoing analysis they realized that they had all the information they needed so no more patients were needed. He said it is common in phase 1 trials that far fewer patients are ultimately required than first anticipated. Re. the length of time it took to get results out he said "we won't rush or compress the science by putting a timeline on it."
stockhouse post 7955784
So now suddenly he refers to the ph II prostate trial as a ph I trial – is it because that is all it has become in thompson’s mind? Again –no follow-up – nothing- but the cult doesn’t mind, BT is God in their eyes.
Can there be any doubt any longer that Dr. Brad Thompson, whether intentionally or otherwise, has misled people about the prostate trial and has never given a reasonable explanation when things changed (a material event requiring disclosure imo) as to why they changed? No, he just simply moves on to the next “big” thing, losing more credibility (if that were possible), except of course, among his cult following.
It is time to demand Thompson voluntarily vacate the chairmanship of onc for the good of the company shareholders and to also demand complete, thorough, honest and public answers from Thompson to reasonable questions and at this year’s AGM and to persist until he provides them.
If he doesn’t provide satisfactory responses, it is time to demand his complete resignation from the company!